Study details
Enrolling now
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
AbbVie
NCT IDNCT07414784ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18–65
Sex
Female only
Locations
1 site in IL
About this study
This Phase 1 study is testing Ethinyl Estradiol in people with healthy volunteers. The primary outcome being measured is Number of Participants with Adverse Events (AEs).
Based on ClinicalTrials.gov records.
PhasePhase 1
DrugEthinyl Estradiol
Routeoral
Primary goalNumber of Participants with Adverse Events (AEs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
ethinylestradiol, progestin (hormonal contraceptive)
Drug routes
oral (Oral Tablet)
Endpoints
Primary: Number of Participants with Adverse Events (AEs)